1800 244 735

Helpline (02) 9874 9777

Oz Buzz Updates: Day 3

Our final daily report from the Huntington’s disease World Congress brings together all the live updates from our twitter feed. Video of both Oz Buzz sessions – with news, interviews and features – is on YouTube now and will be available to watch at HDBuzz.net later this week.

Wednesday, September 14, 2011

8:33 – Jeff and Ed are now live from day 3 of the World Congress on HD!

8:40 – Jeff: HD may be much more common than we thought – Michael Hayden

8:47 – Jeff: HD is an increasing burden on the elderly, who in the past may not have lived long enough to have symptoms – Hayden

9:02 – Ed: More on increased ‘prevalence’ of HD – how it’s more common than we thought

9:07 – Ed: studies in sperm helping to predict whether a CAG repeat in the ‘gray area’ will cause problems for next generation

9:13 – We need to move away from talking about ‘onset’ in Huntington’s – symptoms begin gradually over years – Dr Mark Guttman

9:32 – Huntington’s disease causes a wide variety of symptoms so doctors should always bear it in mind when seeing patients- Elizabeth McKusker

10:36 – Ed’s reporting from the ‘Science: omics’ session – Jeff’s in ‘International models of care’.

10:37 – Ed: ‘omics’ means measuring loads of things at once. Like genomics (looking at tons of genes)

10:45 – Ed: Metabolomics is measuring metabolites – small molecules in blood. Wayne Matson’s done it in HD & finds interesting changes

10:54 – Ed: Levels of a chemical I3PA seem to be reduced in blood of HD patients and HD mice. Not yet clear why but could be useful – Matson

11:02 – Jeff: HD patient care in Australia is difficult because of complex health care administration – Andrew Churchyard

11:00 – Jeff: Significant numbers of HD families don’t interact with the medical system, and we don’t know why – Churchyard

11:11 – Ed: Brain immune cells called microglia are abnormal in HD mice – Dr Blair Leavitt – are they helping or harming?

11:13 – Ed: There are also changes in the mice’s brain blood vessels that could increase the cross-talk between brain & body – Leavitt

11:26 – Jeff: Access to medical services for HD families in South Africa is limited – Amanda Krause

11:34 – Jeff: In black Africans a disease called ‘HD like 2’ looks very much like HD, but is caused by a different mutation – Krause

11:38 – Ed: Ruth Luthi-Carter examines which genes are more and less activated in different mouse models of HD & compares them to humans

11:51 – Ed: These gene activation changes could help us to understand the disease and develop and test new drugs – Luthi-Carter

12:06 – Ed: Proteins do stuff by sticking to each other. Mutant and normal huntingtin stick to different groups of partners – Chris Ross

12:11 – Ed: An international consortium of researchers is using stem cell models to help understand Huntington’s disease

12:18 – Jeff: Francisco Cardoso – new Latin american HD network active at rlah.org

12:20 – Ed: The consortium has figured out the recipe for turning stem cells into the neurons most affected by HD. Very valuable research tool

12:27 – Red Latino-Americana de Huntington: investigación de tratamientos efectivos para la Enfermedad de Huntington

12:43 – Ed: Comparing gene switching and behavior across mouse models shows that different models mimic different aspects of HD Lesley Jones

12:44 – Ed: One of the mouse models called Q150 actually produces less huntingtin protein overall – weird but important to know about – Jones

12:45 – Ed: An HDBuzz article on the different mice used in Huntington’s disease research is coming soon

13:47 – Ed and Jeff are now reporting from the final science session – late breaking hot topics. Jeff is the first speaker in the session!

13:56 – Jeff studies metabolites in several tissues in HD mice. Tissues like brain, fat and liver are all changed differently by the mutation.

14:00 – Metabolic changes Jeff found in HD mouse blood mirror the changes in the brain – could be useful for studying human patients

14:19 – Dimebon showed no benefit for HD in big trial- HORIZON. The quest for treatments for thinking probs continues.

14:21 – However, HORIZON study recruited rapidly and was run efficiently – good news for future trials of upcoming treatments – Bernhard Landwehrmeyer

14:42 – Chemical ‘tattoos’ are added to DNA by enzymes. HD messes this up. HDAC inhibitor drugs should help – a trial’s underway – Larry Marsh

14:50 – There are many different DNA ‘tattoos’ = many ways to try to improve things with drugs. Animal studies will identify best ones – Marsh

15:10 – Jeff: Clare van Eyk uses fruit flies to try and understand how the mutated huntingtin gene kills brain cells

15:12 – ‘RNA’, as well as protein might contribute to brain cells dying – Clare

15:13 – Jennifer Thompson is studying the psychiatric symptoms of HD, like apathy and depression, which can be devastating

15:16 – Apathy is incredibly common in HD, and worsens over time – Thompson

15:18 – Interestingly, depression is also common in HD, but doesn’t seem to change much over time – Thompson

15:36 – Robi Blumenstein of CHDI – like a chess game, we need to think far ahead if we’re going to beat Huntington’s disease

15:40 – Success is a three-legged stool: (1) an effective treatment (2) the ability to test it and (3) enough trial volunteers – Blumenstein

16:00 – Lots of HD family members needed for trials, now & future. Find out how to get involved at Enroll-HD.org

Latest Research Articles

Disappointing news from Novartis about branaplam and the VIBRANT-HD trial

Published date: 9 December, 2022

The pharmaceutical company Novartis has released a community update which announces that they are ending development of branaplam, a huntingtin lowering drug, for possible treatment in Huntington’s disease (HD). This news comes following recent bad news about side effects of branaplam in HD patients, being tested in the VIBRANT-HD clinical trial, dosing of which was ... Read more

Update on the PTC Therapeutics PIVOT-HD Trial

Published date: 2 November, 2022

Recruitment of participants into the US arm of the PTC Therapeutics PIVOT-HD trial has been paused. Since this announcement, there have been a lot of different (and confusing!) headlines about the pause in recruitment. In this article, we will lay out what is going on and what this announcement means. What is the aim of ... Read more

Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials

Published date: 30 September, 2022

In the past week or so, during and following a big HD research conference, two companies developing medicines for Huntington’s disease announced news about their huntingtin-lowering drugs. First, the pharmaceutical company Roche announced plans for a new clinical trial of tominersen. Then, the genetic medicines company Wave Life Sciences shared early data showing that its ... Read more

Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps

Published date: 8 September, 2022

A group of scientists from the EPFL in Lausanne, Switzerland have published a paper in the Journal of the American Chemical Society, describing clumps made up of a fragment of the huntingtin protein. A word that’s commonly used to describe these is “aggregates.” Using very powerful microscopes, the team was able to zoom in and ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 4

Published date: 2 September, 2022

DNA repair and CAG repeat instability The effect of HTT lowering on CAG repeat expansions Welcome to last day of the @hdfcures conference! We’ll only be sharing a few talks from today’s sessions, which focus on DNA repair. The first is from HDBuzz’s very own Jeff Carroll! Jeff will be sharing his work on HTT ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 3

Published date: 1 September, 2022

Pre-clinical work moving toward trials New tools to lower HTT showing promise in animal models Welcome back! The first talk we will be tweeting about today is from Anastasia Khvorova, who will be telling us about her teams work on lowering of Huntingtin using technology called RNAi. One of the problems in studying drug delivery ... Read more